| Dr Richard Anthony Aballay, MD | |
|
620 W 8th St, Kinsley, KS 67547-2329 | |
| (620) 659-3621 | |
| (620) 659-3810 |
| Full Name | Dr Richard Anthony Aballay |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Experience | 19 Years |
| Location | 620 W 8th St, Kinsley, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063577377 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospice Of The Prairie | Dodge city, KS | Home health agency |
| Hospice Of The Prairie | Dodge city, KS | Hospice |
| Edwards County Hospital | Kinsley, KS | Hospital |
| Western Plains Medical Complex | Dodge city, KS | Hospital |
| Pawnee Valley Community Hospital | Larned, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Edwards County Hospital And Healthcare Center | 2264343383 | 7 |
| Edwards County Hospital And Healthcare Center | 2264343383 | 7 |
News Archive
To control reflux symptoms, many people take acid-controlling medications such as Proton Pump Inhibitors, or PPIs. The FDA, however, has issued warnings over the frequent or long-term continued use of PPIs...
Today, CLC bio released a groundbreaking whole-genome de novo assembler that will assemble genomes of any size, including human and plant genomes on a single workstation computer. Equally important, CLC bio's de novo assembler is the first assembler that enables molecular biologists to set up, adjust, and run their large genome de novo assemblies through a graphical user-interface.
The p53 gene has been a well-documented player in the prevention of tumors. It is considered the most frequently mutated gene in human tumors with more than half harboring p53 mutations (Bennett et al., 1999). These mutations often can be caused by disruption in normal p53 function.
Researchers led by Dr. Teppo Särkämö at University of Helsinki, Finland have revealed that caregiver-implemented musical leisure activities, particularly singing, are cognitively and emotionally beneficial especially in the early stages of dementia. The findings could help improve dementia care and better target the use of music in different stages of dementia.
Synthetic Biologics, Inc., a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today the pricing of an underwritten public offering of 11,500,000 shares of common stock at a public offering price of $1.00 per share.
› Verified 2 days ago
| Entity Name | Northeastern Oklahoma Community Health Centers, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518070481 PECOS PAC ID: 3678482635 Enrollment ID: O20031104000417 |
News Archive
To control reflux symptoms, many people take acid-controlling medications such as Proton Pump Inhibitors, or PPIs. The FDA, however, has issued warnings over the frequent or long-term continued use of PPIs...
Today, CLC bio released a groundbreaking whole-genome de novo assembler that will assemble genomes of any size, including human and plant genomes on a single workstation computer. Equally important, CLC bio's de novo assembler is the first assembler that enables molecular biologists to set up, adjust, and run their large genome de novo assemblies through a graphical user-interface.
The p53 gene has been a well-documented player in the prevention of tumors. It is considered the most frequently mutated gene in human tumors with more than half harboring p53 mutations (Bennett et al., 1999). These mutations often can be caused by disruption in normal p53 function.
Researchers led by Dr. Teppo Särkämö at University of Helsinki, Finland have revealed that caregiver-implemented musical leisure activities, particularly singing, are cognitively and emotionally beneficial especially in the early stages of dementia. The findings could help improve dementia care and better target the use of music in different stages of dementia.
Synthetic Biologics, Inc., a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today the pricing of an underwritten public offering of 11,500,000 shares of common stock at a public offering price of $1.00 per share.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Richard Anthony Aballay, MD Po Box 751, Hulbert, OK 74441-0751 Ph: (918) 772-3390 | Dr Richard Anthony Aballay, MD 620 W 8th St, Kinsley, KS 67547-2329 Ph: (620) 659-3621 |
News Archive
To control reflux symptoms, many people take acid-controlling medications such as Proton Pump Inhibitors, or PPIs. The FDA, however, has issued warnings over the frequent or long-term continued use of PPIs...
Today, CLC bio released a groundbreaking whole-genome de novo assembler that will assemble genomes of any size, including human and plant genomes on a single workstation computer. Equally important, CLC bio's de novo assembler is the first assembler that enables molecular biologists to set up, adjust, and run their large genome de novo assemblies through a graphical user-interface.
The p53 gene has been a well-documented player in the prevention of tumors. It is considered the most frequently mutated gene in human tumors with more than half harboring p53 mutations (Bennett et al., 1999). These mutations often can be caused by disruption in normal p53 function.
Researchers led by Dr. Teppo Särkämö at University of Helsinki, Finland have revealed that caregiver-implemented musical leisure activities, particularly singing, are cognitively and emotionally beneficial especially in the early stages of dementia. The findings could help improve dementia care and better target the use of music in different stages of dementia.
Synthetic Biologics, Inc., a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today the pricing of an underwritten public offering of 11,500,000 shares of common stock at a public offering price of $1.00 per share.
› Verified 2 days ago